Investor relations

We are a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites.

CSE:NM

Novamind Inc.

Share capitalization
Issued & outstanding: 41,482,017
Reserved for issuance: 1,281,250
Dilutive securities: 6,325,292

Canadian Securities Exchange
Latest Novamind
presentation
View presentation
Latest Novamind
fact sheet
View fact sheet

Financial statements and public disclosure documents

YearQuarterDateReportDownload
2021Q1March 1, 2021Interim Financial Statements View PDF
2021Q1March 1, 2021Management’s Discussion and Analysis View PDF
2020Q4December 31, 2020Filing Statement View PDF
2020Q4November 12, 2020Material Change Report View PDF
2020Q3July 3, 2020Material Change Report View PDF

Interim Financial Statements

March 1, 2021

View PDF

Q12021

Management’s Discussion and Analysis

March 1, 2021

View PDF

Q12021

Filing Statement

December 31, 2020

View PDF

Q42020

Material Change Report

November 12, 2020

View PDF

Q42020

Material Change Report

July 3, 2020

View PDF

Q32020

Advisors

Transfer agent

Marrelli Trust Company Limited

Legal Counsel

McMillan LLP

Auditor

DMCL LLP